NIH R21, R33, and Phased Innovation Award

Full title:  Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders 
 

The purpose of this Funding Opportunity Announcement (FOA) issued by the National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), the National Institute of Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) is to facilitate the development of agonist and antagonist PET and SPECT probes for molecular targets that are implicated in the pathophysiology of brain and behavioral disorders (e.g., receptors, intracellular messengers, disease-related proteins). The use of radiotracers for imaging molecular events in preclinical and clinical studies is essential for understanding the circuitry that underlies normal brain function and the pathophysiology of brain disorders. The long-term goal of this FOA is to facilitate the broad application of neuroimaging probes in pathophysiological studies, drug discovery/development research, and in biomarker development//qualification studies as quantifiable indicators of disease progression and treatment efficacy.

http://grants1.nih.gov/grants/guide/pa-files/PA-06-461.html